Amneal to Report First Quarter 2025 Results on May 2, 2025

Rhea-AI Summary

Amneal Pharmaceuticals (NASDAQ: AMRX) has scheduled the release of its first quarter 2025 financial results for Friday, May 2, 2025, before market open. The company will host an audio webcast at 8:30 a.m. ET on the same day.

Investors and interested parties can access the webcast through the company's Investor Relations website at https://investors.amneal.com. For those preferring a conference call, dial-in options are available at 1 (833) 470-1428 for U.S. participants, with international numbers also provided. The access code for the call is 170097.

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its first quarter 2025 financial results on Friday, May 2, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access code for the call is 170097. A replay of the conference call will be posted shortly after the call.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250408714062/en/

Investor Contact

Anthony DiMeo

VP, Investor Relations

anthony.dimeo@amneal.com

Source: Amneal Pharmaceuticals, Inc.

FAQ

When will Amneal Pharmaceuticals (AMRX) release Q1 2025 earnings?

Amneal will release Q1 2025 earnings on Friday, May 2, 2025, before market open.

How can investors access AMRX's Q1 2025 earnings call?

Investors can join via webcast at investors.amneal.com or dial 1 (833) 470-1428 (U.S.) using access code 170097.

What time is Amneal's (AMRX) Q1 2025 earnings webcast?

The earnings webcast will begin at 8:30 a.m. ET on May 2, 2025.

Will there be a replay available for AMRX's Q1 2025 earnings call?

Yes, a replay of the conference call will be posted shortly after the call.